Thirty-two UCSF scientists are among the most influential individuals in their respective fields, according to the most recent analysis of research citations by the science and intellectual property company, Clarivate.
UCSF's Adam Boxer, MD, PhD, and Harvard neurologist Reisa Sperling, MD, review the history of clinical trials over the past 30 years in Alzheimer’s research with what was learned and how new biomarkers and clinical trial approaches are being used to find more effective treatments in a more efficient way than in the past.
UCSF researchers developed an approach to measure an over-the-counter allergy medication’s effectiveness in repairing brain damage from multiple sclerosis (MS), making it possible to also assess future therapies for the disorder.
When we inhale an airborne virus, our lung cells take on the role of immune system first responders. Catera Wilder, PhD, studies the molecular details of this response and how it can go awry, causing the body to damage its own tissue and cells.
A $147 million grant will expand diversity among Alzheimer’s disease research participants, and involve partners from UCSF, the San Francisco VA Medical Center, and the Northern California Institute for Research and Education.
For many women, breast cancer screening with a three-dimensional imaging technique called digital breast tomosynthesis (DBT) may not offer advantages over digital mammography, but for some it may reduce the chance of an advanced cancer diagnosis, according to a new JAMA study.